Across 160 million years of mammalian history, the immune system quietly refined a small protein — lactoferricin — into an increasingly precise weapon against bacterial infection. Researchers at the University of Oregon have now reconstructed that evolutionary journey in the laboratory, resurrecting ancient versions of the peptide to trace how single amino-acid changes produced dramatic leaps in antibacterial power. In an era when conventional antibiotics are losing ground to resistant bacteria, this deep reading of evolutionary memory offers not a ready cure, but something perhaps more valuab
Ancient mammal immune peptides reveal evolutionary path to fighting antibiotic-resistant bacteria
Small changes in these domains could have such large effects
Mark
So they actually rebuilt proteins that haven't existed for 160 million years? How is that even possible?
Mimi
They compared modern sequences from living mammals and used statistical methods to infer what the ancestral versions probably looked like. It's like reconstructing a family tree of the protein itself.
Luke
But that's inference, not certainty. They're making educated guesses based on patterns. The ancient peptides never actually existed in a test tube until the researchers synthesized them.
Mimi
True, but the fact that the reconstructed versions worked—that they actually killed bacteria—suggests the inference was sound. The biology validated the math.
Mark
And they found that one tiny change made a huge difference in how well it fought bacteria?
Mimi
One amino acid swap at position 8. Glutamine became arginine. That single substitution made the peptide far more potent against Pseudomonas aeruginosa.
Luke
Against that one bacterium. Against Staphylococcus aureus, the same change was necessary but not sufficient. The story is more complicated than a single magic mutation.
Mark
So why does this matter if these peptides aren't drugs yet?
Mimi
Because it shows evolution can solve the antibiotic resistance problem through small, specific changes. It gives scientists a roadmap—actual examples of what works and why.
Luke
It gives them possibilities to investigate. But the researchers themselves say bacteria can evolve resistance to these peptides too. This is a starting point, not a solution.
Mark
What's the real barrier to turning this into medicine?
Mimi
Stability, mainly. These peptides break down quickly in the body. Conventional antibiotics are much more durable.
Luke
And we don't know yet whether the lab results will translate to living organisms. Low-nutrient medium is very different from the human body.
Le Pouls
- Antibiotic resistance is accelerating faster than new drugs can be developed, making the search for alternative antimicrobial strategies a matter of growing urgency.
- By resurrecting peptides from extinct mammalian ancestors, scientists discovered that a single molecular swap — one amino acid out of twenty-five — could dramatically amplify a peptide's ability to kill dangerous bacteria like Pseudomonas aeruginosa.
- The findings complicate any simple narrative of evolutionary progress: some ancient peptide forms outperformed their modern human descendants against specific bacterial targets, revealing that evolution optimizes for context, not absolute strength.
- Antimicrobial peptides still face serious obstacles as drugs — they degrade quickly in the body and were tested only under simplified laboratory conditions — leaving a significant gap between discovery and clinical application.
- The research is now pointing toward a new design philosophy: rather than engineering the most potent peptide possible, scientists may use the evolutionary record to anticipate bacterial resistance and build more durable, strategically refined molecules.
Across 160 million years of mammalian history, the immune system quietly refined a small protein — lactoferricin — into an increasingly precise weapon against bacterial infection. Researchers at the University of Oregon have now reconstructed that evolutionary journey in the laboratory, resurrecting ancient versions of the peptide to trace how single amino-acid changes produced dramatic leaps in antibacterial power. In an era when conventional antibiotics are losing ground to resistant bacteria, this deep reading of evolutionary memory offers not a ready cure, but something perhaps more valuable: a blueprint for how nature itself solved the problem of bacterial adaptation.
A research team at the University of Oregon has done something quietly remarkable: they reached 160 million years into the past to resurrect ancient immune proteins, then watched evolution replay itself in the laboratory. The subject of their reconstruction is lactoferricin, a short antimicrobial peptide found today in milk, saliva, tears, and intestinal mucus — a front-line defender that mammals have carried and refined since the age of early placental life.
Using ancestral sequence reconstruction, the researchers compared hundreds of modern vertebrate protein sequences to statistically infer what lactoferricin looked like in long-extinct common ancestors. They then synthesized these predicted ancient forms and tested them against four disease-causing bacteria. The earliest reconstructed version already showed meaningful antibacterial activity. A later ancestral form was substantially stronger. Modern bovine lactoferricin proved most potent of all, eliminating all detectable colonies of Pseudomonas aeruginosa within two hours.
The most striking finding was how little change was required to produce large effects. The two earliest ancestral peptides differ at only three positions in their sequence, yet one of those differences — a single amino acid swap at position 8, from glutamine to arginine — was both necessary and sufficient to dramatically boost activity against P. aeruginosa. Against Staphylococcus aureus, that same change was necessary but not enough on its own, hinting that evolution worked through multiple reinforcing modifications rather than a single decisive mutation.
The story continued into recent primate history. At position 5, humans and many monkeys carry a different amino acid than other great apes. When researchers introduced the great-ape variant into human lactoferricin, the resulting peptide significantly strengthened activity against several Staphylococcus species — suggesting the human lineage may have traded some antibacterial potency for other evolutionary advantages.
These peptides are not yet drugs. They degrade too quickly in the body, and the experiments were conducted under simplified laboratory conditions rather than the complex biochemical environment of a living organism. But the peptides showed no significant toxicity to red blood cells, a promising early safety signal. More importantly, the research offers something conceptually valuable: a detailed evolutionary map of how nature navigated the arms race against bacteria over geological time. Senior author Matt Barber noted that bacteria can evolve resistance to antimicrobial peptides just as they do to conventional antibiotics — meaning the goal is not simply to find the strongest molecule, but to understand the structural logic of durability. The deep past, it turns out, may be one of the most useful guides to the future of medicine.
A team at the University of Oregon has reconstructed antimicrobial peptides from mammal ancestors that lived roughly 160 million years ago, then watched those ancient immune defenses evolve in the laboratory. The work traces how a small protein region called lactoferricin—found today in milk, tears, saliva, and intestinal mucus—gradually became more lethal to bacteria through incremental changes in its chemical structure.
Lactoferrin, the larger protein containing lactoferricin, emerged after a gene duplication in early placental mammals. The researchers focused on a 25-amino-acid stretch of this peptide and used ancestral sequence reconstruction to statistically infer what the protein looked like in extinct common ancestors. They compared 376 sequences from modern vertebrates, then synthesized the predicted ancient versions and tested them against four disease-causing bacteria: Pseudomonas aeruginosa, Escherichia coli, Staphylococcus aureus, and Streptococcus agalactiae.
The earliest reconstructed version, labeled AncLFcin1, already showed antimicrobial punch. At higher concentrations—400 micrograms per milliliter against P. aeruginosa, 800 against E. coli—it reduced bacterial growth by more than 50 percent. A later ancestral form, AncLFcin2, was substantially stronger, inhibiting growth at concentrations as low as 50 micrograms per milliliter. Modern bovine lactoferricin proved most potent, and against P. aeruginosa it killed all detectable colonies within two hours. The modern human version was less effective than the bovine peptide but still formidable, producing a 10,000-fold reduction in bacterial viability after 24 hours.
What surprised the researchers was how a single amino-acid substitution could drive such dramatic improvements. AncLFcin1 and AncLFcin2 differ at only three positions in their sequence. At position 8, AncLFcin2 carries arginine instead of glutamine—a change designated Q8R. Experiments showed this one swap was both necessary and sufficient to substantially increase activity against P. aeruginosa. Against S. aureus, the same substitution was necessary but not sufficient by itself to recreate the full antimicrobial effect, suggesting the evolution of these peptides involved multiple reinforcing changes rather than a single master switch. Senior author Matt Barber, an evolutionary biologist at Oregon, noted the counterintuitive finding: "What was surprising and unexpected was how small changes in these domains could have such large effects."
The peptide continued evolving even in recent primate history. Two positions showed evidence of diversifying natural selection. At position 5, humans and many monkeys carry glutamine, while other great apes have arginine. When researchers introduced the great-ape version into human lactoferricin, the resulting peptide significantly strengthened activity against S. aureus and suppressed several additional Staphylococcus species. The pattern revealed that antimicrobial evolution was not a simple march toward ever-increasing strength—some ancestral forms were actually more bactericidal against particular bacteria than the modern human peptide.
These reconstructed peptides are not yet ready-made drugs. Antimicrobial peptides generally lack the stability of conventional antibiotics and break down quickly inside the body. The experiments also used low-nutrient laboratory conditions rather than the complex environment of a living mammal, though general patterns held across different media tested. The peptides did not significantly damage bovine red blood cells, a positive sign for safety, but much work remains before any therapeutic application.
What the research does offer is a detailed map of how evolution solved the problem of bacterial resistance through structural refinement. Barber cautioned that bacteria can evolve resistance to antimicrobial peptides just as readily as they do to conventional antibiotics. Understanding how these natural defenses changed over millions of years could help researchers anticipate weaknesses and design more durable molecules rather than simply chasing the strongest peptide. The evolutionary record, in other words, becomes a guide for engineering the next generation of antimicrobial treatments.
Citations marquantes
Evolution is essentially a billions-year-old science experiment— Matt Barber, evolutionary biologist at University of Oregon
We're definitely interested in whether by resurrecting or engineering some enhanced antimicrobial peptides, we could use these as therapeutics down the road— Matt Barber
Envie de l'histoire complète ?
Lire l'original sur The Brighter Side of News ↗
Health & Medicine